| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President & CEO | Chief Financial Officer
2 companies
James E Dentzer is President & CEO at CRIS, with reported holdings spanning 2 companies. James E Dentzer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $126K at current prices.
James E Dentzer's largest disclosed position is in CRIS as President & CEO, worth about $106K. The CRIS filings lean toward selling, a net 23,120 shares.
James E Dentzer has 29 Form 4 filings on record from March 2016 to July 2026, across 2 companies: Director at Imunon (IMNN), 2022–2026; President & CEO at Curis (CRIS), 2016–2026.
The 38 reported transactions were 25 option or other derivative awards, 8 open-market sales, 4 stock awards and 1 conversion.
Counted by filing, the open-market trades come to no purchases and 4 sales worth about $92K.
The largest open-market sale was 5,377 shares of CRIS at an average $10.75 on January 26, 2021, about $58K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 31, 2022 | CRIS Curis Inc | President & CEO | Sell | 5,500 | $3.12 | $17,149.66 | -7.8% | -68.9% | -77.0% | |
| Jan 26, 2021 | CRIS Curis Inc | President & CEO | Sell | 5,377 | $10.75 | $57,779.71 | -7.4% | - | - | |
| Jan 24, 2020 | CRIS Curis Inc | President & CEO | Sell | 6,752 | $1.67 | $11,257.98 | -13.8% | - | - | |
| Jan 24, 2019 | CRIS Curis Inc | President & CEO | Sell | 5,491 | $1.13 | $6,189.70 | -11.7% | - | - |